Zylo, Hoth expand relationship see more
Mr. Robb Knie, Chief Executive Officer of Hoth, commented, “We are pleased to expand our partnership with Zylö and look forward to working together as our therapeutic for Lupus patients continues through the next phase of development. This small equity investment in Zylö is a further commitment to our belief in Zylö’s science and team.”
Stated Scott Pancoast, CEO of Zylö Therapeutics, “Partnering with Hoth in 2019 was an important step in propelling our lupus program forward. This equity investment in Zylö stock represents an expansion of the partnership and is a win-win for the two companies.”
According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month.
About Zylö Therapeutics, Inc.
Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; http://www.zylotherapeutics.com/
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). To learn more, please visit www.hoththerapeutics.com.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of AEA-loaded Z-pods™, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth’s current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption “Risk Factors” in Hoth’s Form 10K for the period ending December 31, 2018, and Hoth’s other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
Zylo nominated to BIO contest see more
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has been nominated as a finalist for the Buzz of BIO Contest, which recognizes the most innovative companies in the life sciences.
BIO is the world’s largest biotech association. Among other conferences, the association sponsors the 2020 BIO International Convention each year, with almost 20,000 attendees. It takes place in San Diego this year in June, where the winner of Buzz of BIO will be announced.
Each finalist was asked to submit the three compelling reasons to vote for them. Zylö’s reasons are summarized as follows:
1. Zylö’s endocannabinoid-loaded Z-pod™ solution is showing striking results in a lupus model... Lupus affects women and people of color disproportionately and has tragic quality-of-life ramifications.
2. Our nitric-oxide-releasing Z-pod™ topical solution is showing compelling results in an Erectile Dysfunction model (where ED is secondary to prostatectomy, a condition that is not treatable with Viagra et al.); this solution should translate well as a treatment for older women with sexual dysfunction.
3. Our technology is disruptive and affordable... and we plan on keeping it that way.
Scott Pancoast, Zylö CEO and founder, stated “This is a huge honor and reflects the incredible innovation taking place in our lab from Andrew Draganski PhD, scientific founder, and scientists Eric Renne (M.S., U.C.) and Clay Tucker (M.S., Clemson). We encourage folks in the Upstate to vote in an effort to continue this region’s winning ways in the world of technological innovation.”
About Zylö Therapeutics: Zylö has developed a breakthrough topical delivery system that extends the duration-of-effect, improves the solubility/targeting, and/or enhances the product performance of many therapeutic agents. Notably, the Z-pod™ technology platform has enabled the Patchless Patch™ concept and has successfully harnessed the therapeutic potential of nitric oxide, one of the most powerful—and short-lived—biomolecules produced by our bodies. For more details please visit our web site, www.zylotherapeutics.com and follow us on Twitter (@ZyloTherapies).
Greenville, SC gains more accolades as a key cog in the state's emerging knowledge economy see more
Greenville and South Carolina are in the national spotlight again as among America's emerging knowledge economy destinations. SCBIO supporters Zylo Therapeutics, KIYATEC, VentureSouth and Chartspan are among the features companies in Bloomberg Businessweek's fabulous article. Read on for the full story.
SEMDA Medtech to Showcase Over 20 High-Impact New Technologies, National Speakers at May 2-4 ConferenceLeading-edge innovators, top presenters headed for SEMDA's Medtech 2018 in South Carolina see more
Leading-edge innovators present for recognition, reward at annual gathering of Southeastern who’s who in medical technology, devices and diagnostics
Greenville, SC – April 27, 2018 – At least 23 organizations ranging from start-ups to well-established companies have been accepted to present their latest, ground-breaking innovations to entrepreneurs, innovators, angel investors and business leaders from across the life sciences space as the Southeastern Medical Device Association (SEMDA) 2018 Medtech Conference convenes in Greenville, SC May 2-4, 2018.
SEMDA -- a non-profit trade association focused on making the Southeast a world-class region for medical technology, device, and diagnostic companies – has invited 23 finalist companies to present at PitchRounds 2018 – a highly targeted venue for both “Seed” companies as well as later-stage organizations to present innovative ideas to panels of institutional investors, regulatory leaders, venture capital directors, IP experts and others.
Companies from seven Southeastern states will present ground-breaking ideas and technologies to hundreds of industry leaders. Host state South Carolina leads the way with 10 companies invited to present, followed by Georgia and Florida with three companies each. North Carolina, Alabama, Virginia and Tennessee are also represented.
Among the South Carolina companies invited to present are Zylo Therapeutics, Accessible Diagnostics, KIYATEC and Moterum from host city Greenville, while Charleston’s Sanguine Technologies and Cryogenix, and Columbia’s Proof Biotechnologies are also invited.
Invitees from Georgia include Intent Solutions and nfant, both of Atlanta, while North Carolina entries include Diamond Othopedic of Charlotte. Memphis, Tennessee’s Sweetbio, Birmingham’s Circulogene and Nashville’s Raiven are also featured invitees.
Twelve Early-stage companies from the Carolinas, Alabama and Florida have been invited to present at PitchRounds, with four finalists to be selected to compete for $10,000 in prize money, while getting to meet investors and partners at sessions and networking receptions. SCBIO, SCRA and global law firm Eversheds Sutherland are co-sponsors of PitchRounds.
Among the featured speakers committed to present at the conference are keynoter Joe Lee, Executive Director of Life Sciences for JP Morgan; Andy Fish, Chief Strategy Officer of AdvaMed; and Denise Hines, North American Chair of the Health Information & Management Systems Society and current CEO of eHealth Services Group.
Joe Lee is Executive Director of Life Sciences for JP Morgan and leads the Middle Market Banking coverage of life science companies across the Southeast. Widely respected in life science industry circles, Mr. Lee will discuss key opportunity areas for growth in the Southeast and provide rapid-growth companies with counsel on how to prepare their organizations for success in the competitive space.
Andrew Fish is Chief Strategy Officer of AdvaMed, the leading trade association advancing medical technology in the U.S. and around the world. As chief strategy officer, Mr. Fish leads the association’s strategic planning, oversees AdvaMed's global, regulatory, and payment departments, and coordinates the development and operations of AdvaMed’s membership divisions and sectors.
Dr. Denise Hines is current Chair of the North America Board of the Health Information & Management Systems Society (HIMSS), and is actively involved in HIMSS’ Women in Health IT initiatives that promote diversity and recognition. She is CEO of eHealth Services Group and serves as Executive Director of Georgia’s statewide health information exchange (HIE).
“The Southeastern medtech industry as a whole shows incredible growth and promise, and the diverse entries from across the region reflect that growth,” said Jason Rupp, Executive Director of SEMDA. “PitchRounds gives us the chance to see the future come to life before our eyes with cutting-edge innovation and game-changing advancements in medical technology, devices and diagnostics from some of America’s brightest minds.”
The SEMDA conference typically attracts more than 400 executives in medtech and life sciences from throughout the United States and has become a must-attend for the medtech community. Registration is strong but space is still available, noted Mr. Rupp. Persons interested in attending can review the agenda, speakers and registration details online at http://www.semda.net.
“These presenters and companies demonstrate that SEMDA has evolved into a truly regional organization that embraces and represents a diverse collective of medtech startups, universities, corporate organizations, investment resources, suppliers and capabilities from across the southeastern United States,” Mr. Rupp added.
The Southeastern Medical Device Association (SEMDA) is a regional non-profit trade association that supports and promotes medical device and medical device data system (MDDS) companies in the Southeast. Created in 2004, the association provides unique educational resources to accelerate device development and achieve commercial success with access to funding, education, and networking opportunities for medical device companies, inventors, physicians, investors, tech transfer offices, universities, sponsors, and service providers interested in growing the medical device industry in the Southeast.
Invited and scheduled to present at PitchRounds 2018
LATER STAGE (RAISING SERIES A OR LATER)
Kayla Rodriguez Graff
Sanguine Technologies Inc.
Accessible Diagnostics, LLC
Luke Marshall, Ph.D.
Aravis BioTech LLC
DiaTech Diabetes Technology
Proof Biotechnologies, Inc
PivotSC LLC/ XtremedX